David M. Spencer
Keine laufenden Positionen mehr
Karriereverlauf von David M. Spencer
Ehemalige bekannte Positionen von David M. Spencer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 14.07.2004 | 01.03.2019 |
| Gründer | 14.07.2004 | 01.03.2019 | |
| KIROMIC BIOPHARMA, INC. | Direktor/Vorstandsmitglied | 01.10.2019 | - |
| Technik-/Wissenschafts-/F&E-Leiter | 01.10.2019 | - | |
| Baylor College of Medicine | Corporate Officer/Principal | - | - |
Ausbildung von David M. Spencer
| Massachusetts Institute of Technology | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KIROMIC BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
- Börse
- Insiders
- David M. Spencer
- Erfahrung
